Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

TANLOR 1,000 MG TABLET

methocarbamol
$8.3480per EA

Strength

1000 mg/1

Manufacturer

Forte Bio-Pharma

NDC

72245087310

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

METHOCARBAMOL

Approval Type

Generic (ANDA)

FDA Application

ANDA212707

On Market Since

8/30/2024

Pharmacological Classes

Centrally-mediated Muscle Relaxation
Muscle Relaxant

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

0.0%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CYCLOBENZAPRINE 10 MG TABLET
Generic
00093342201•Teva Pharmaceuticals USA Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
00093342205•Teva Pharmaceuticals USA Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
00093342210•Teva Pharmaceuticals USA Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
00904740161•Major Pharmaceuticals
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
10702000710•KVK-Tech Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
10702000750•KVK-Tech Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
16571078301•Rising Pharma Holdings Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
16571078310•Rising Pharma Holdings Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
16571078350•Rising Pharma Holdings Inc.
$0.0176
per EA
CYCLOBENZAPRINE 10 MG TABLET
Generic
29300041501•Unichem Pharmaceuticals (USA) Inc.
$0.0176
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy